Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane
Marcin Kubeczko(The Maria Sklodowska-Curie National Research Institute of Oncology), Fara Brasó-Maristany(Breast Cancer Research Foundation), Sandra Cobo(Breast Cancer Research Foundation), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Jesús Soberino(Hospital Quirónsalud Barcelona), Aleksandra Leśniak(The Maria Sklodowska-Curie National Research Institute of Oncology), Bartłomiej Pyciński(Silesian Center for Heart Disease), Julia Maues(Grace (United States)), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Patricia Villagrasa, A. Prat(Cancer Clinic), B. Adamo(Hospital Clínic de Barcelona), Ewa Chmielik(National Institute of Oncology), Michal Jarzab(The Maria Sklodowska-Curie National Research Institute of Oncology), Milana Bergamino(Cancer Clinic), Francisco Pardo(Oryzon Genomics (Spain)), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María Julia Hernández Vidal(Cancer Clinic), Malgorzata Oczko-Wojciechowska(National Institute of Oncology), Eva Ciruelos(Hospital Universitario 12 De Octubre), Maria Rey(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Esther Carcelero(Hospital Clínic de Barcelona), Esther Sanfeliu(Hospital Clínic de Barcelona), Angela Aguirre
Cited by 0
Related Papers
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
|Cancer Research|2017|480
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271